Drugs / CS-121
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07657780 | Jun 2026 → Mar 2028 expected | hypertriglyceridemia | CorrectSequence Therapeutics Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07371767 | Jan 2026 → Oct 2027 expected | hyperlipoproteinemia | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT07176923 | Oct 2025 → Dec 2026 expected | familial chylomicronemia syndrome | CorrectSequence Therapeutics Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | CorrectSequence Therapeutics Co., Ltd | Results The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia correctsequence.com ↗
In the dose-escalation IIT for CS-121, his fasting TG level dropped significantly within three days after a single low-dose administration, with no adverse events. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | CorrectSequence Therapeutics Co., Ltd | The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia correctsequence.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS-121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07657780 ↗ |
| Action | Inhibit | “designed to reduce ApoC3 protein expression” NCT07176923 ↗ |
| Modality | CRISPR / gene editing | “in vivo base editing therapy” NCT07371767 ↗ |
| Route | Intravenous | “a single intravenous infusion of CS-121” NCT07176923 ↗ |
| Target | APOC3 | “targeted editing of the APOC3 gene” NCT07176923 ↗ |